

TRISTEL plc
("Tristel" or the "Company")

Capital Markets Day video update

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the recording of the Capital Markets Day held on Tuesday, 29 July 2025 is now available on the Company's website.

To view the recording, please see here: [Investor Hub - WE HAVE CHEMISTRY](#)

For further information please contact:

Tristel plc
Matt Sassone, Chief Executive Officer

Via Walbrook PR
www.investors.tristel.com

Walbrook PR Ltd
Paul McManus / Lianne Applegarth / Anna Dunphy

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893/ 07584 391 303/ 07876 741 001

Cavendish Capital Markets Ltd
Geoff Nash / Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

Tel: 020 7220 0500



About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRASSUFLMEISEIA